Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Inclusion Criteria: * Signed ICF (Informed Consent Form) * Subject-reported history of Drye Eye Disease (DED) in both eyes * Ability and willingness to follow instructions, including participation in all study assessments and visits Exclusion Criteria: * Women who are pregnant, nursing or planning pregnancy * Unwillingness to submit a blood pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control * Clinically significant slit-lamp findings or abnormal lid anatomy at screening and Visit 1 * Ocular/peri-ocular malignancy * History of herpetic keratitis * Active ocular allergies or ocular allergies that are expected to be active during the study * Ongoing ocular or systemic infection * Wear contact lenses within 1 month prior to screening or anticipated use of contact lenses during the study * Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have planned ocular and/or lid surgeries over the study period * Presence of uncontrolled systemic diseases * Presence of known allergy and/or sensitivity to the study drug or saline components * Use of any topical steroids treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 2 months prior to screening